Sensorion announces results from SENS-111 Phase 2b trial in acute unilateral vestibulopathy. pdfread

Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover. pdfRead

Sensorion reports its 2019 first half results - Signature of a framework agreement with Institut Pasteur in gene therapy - Financial position strengthened with the issuance of a €20m mandatory convertible bond. pdfRead

Sensorion announces a poster presentation of new SENS-401 preclinical data at SFN 2019 in Chicago. pdfRead

Sensorion announces the last patient’s last visit in SENS-111 Phase 2 clinical trial. pdfRead

Pipeline

20190603 pipeline

Enregistrer

Patient center

Corporate presentation

Next events